Shanghai Institute of Materia Medical
JV established: Shanghai Runshi Pharma Technology Co.
Co-developing 4 small molecule new drug candidates
NonWith Simmitinib and 3 other products entering clinical trial stage
Email: cspc@cspc.cn
Email: cspc@cspc.cn
Communication and Cooperation
Communication and Cooperation
The Group has always attached great importance to the cooperation and exchanges with domestic and international scientific research organizations, and we closely follow the development trend of advanced technologies. The Group maintains close partnerships with various organizations.
Shanghai Institute of Materia Medical
JV established: Shanghai Runshi Pharma Technology Co.
Co-developing 4 small molecule new drug candidates
NonWith Simmitinib and 3 other products entering clinical trial stage
Shanghai Institute of Materia Medical
Columbia University Drug discovery joint lab
SYHA1 402 commenced clinical trial
Tianjin University
CADD joint lab
Early-stage screening platform for small
molecules
SYHA121-28 is about to enter into pivotal clinical trial
Tianjin University
Established AlaMab
Co-op on first-in-class target discovery and antibody development
ALMB0166 & ALMB0168 have started clinical trials
Sichuan University
Formed strategic partnership
SKLB1028 entering pivotal clinical trial stage
Teva Pharmaceutical
Co-development on multiple new preparations
lrinotecan liposome filed in China and the U.S.simultaneously; will apply for marketingregistration soon in China
Amphotericin B liposome applied in China and the U.S. simultaneously
The Group actively seeks various cooperation opportunities and looks for acquisition targets with strong R&D capabilities in the biopharmaceutical field to further
supplement the pipeline of products under development. Future cooperation objectives will be mainly large and small molecule new drugs that are about to be approved for marketing, which will enrich the new drug list that are potentially to be launched in the next few years. Relying on the Group's strong R&D capabilities, the number of new products will see a rapid increase in the next few years. At the same time, our R&D team has been working on seeking new cooperation opportunities with global scientific research institutions and technology companies.
Entered into a strategic partnership and license agreement with Flame Biosciences, Inc., a U.S. innovative pharmaceutical company, to out-license the exclusive rights outside of Greater China of the Group’s drug candidate NBL-015 (an anti-Claudin 18.2 monoclonal antibody) and two new bispecific antibodies to be developed based on the Group’s NovaTE bispecific antibody technology platform.
Entered into a collaboration with Beta Pharma (Shanghai) Company Limited to obtain the exclusive product license and commercialization rights of rezetinib mesylate capsules (BPI-7711) (a third generation irreversible EGFR-TKI for the treatment of non-small cell lung cancer) in China.
Entered into a collaboration with Keymed Bioscience (Chengdu) Co., Ltd. (“Chengdu Keymed”) to obtain the exclusive product license and commercialization rights of CM310 (an anti-IL-4Rα recombinant humanized monoclonal antibody) for moderate to severe asthma and chronic obstructive pulmonary disease (COPD) in China.
Entered into a collaboration with Chengdu Keymed to obtain the exclusive product license and commercialization of CM326 (an anti-TSPL recombinant humanized monoclonal antibody) for moderate to severe asthma and chronic obstructive pulmonary disease (COPD) and other respiratory system diseases in China.
Entered into a strategic alliance agreement with Chengdu Keymed to cooperate on the clinical development and commercialization of a variety of nervous system disease products.
Entered into a collaboration with Jiangsu Alphamab Oncology Co., Ltd. to obtain the exclusive product license and commercialization rights of KN026 (a HER2-targeted bispecific antibody) for breast cancer and gastric cancer in China.
Acquired 51% equity interest in Guangzhou Recomgen Biotech Co., Ltd. (“Recomgen Biotech”) in February 2022. Mingfule (銘復樂) (recombinant human TNK tissue-type plasminogen activator for injection), a marketed product of Recomgen Biotech, is a third-generation specific thrombolytic drug with intellectual property rights for the treatment of thrombolysis in patients with acute myocardial infarction within 6 hours of onset. The product is currently undergoing Phase III trial (TRACE II) for the indication of thrombolysis in cerebral infarction, with a huge potential market.
Entered into an exclusive license agreement with Elevation Oncology, Inc. (“Elevation Oncology”) for the development and commercialization of the Group’s SYSA1801, a novel (first-in-class) anti-Claudin 18.2 antibody-drug conjugate (ADC) (the “Product”) outside of Greater China (including mainland China, Hong Kong, Macau and Taiwan).
